US FDA Won't Budge On Nitrosamines Compliance Despite Complaints Of Possible Drug Shortages

Industry requests for deadline extensions, short-duration adjustments and other accommodations go nowhere as FDA expresses concerns about nitrosamines’ mutagenic potency.